Want to see IQV full AI Analyst Report?
IQV Stock Chart & Stats
$176.46
-$0.07(-0.03%)
At close: 4:00 PM EST
$176.46
-$0.07(-0.03%)
Day’s Range― - ―
52-Week Range$154.50 - $247.05
Previous CloseN/A
Volume300.39K
Average Volume (3M)1.42M
Market Cap
$34.42B
Enterprise Value$43.05K
Total Cash (Recent Filing)$1.95B
Total Debt (Recent Filing)$16.07B
Price to Earnings (P/E)25.3
Beta0.84
Next Earnings
Jul 28, 2026EPS Estimate
3.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.14
Shares Outstanding166,900,000
10 Day Avg. Volume1,098,930
30 Day Avg. Volume1,415,541
Financial Highlights & Ratios
PEG Ratio6.34
Price to Book (P/B)5.96
Price to Sales (P/S)2.38
P/FCF Ratio18.89
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$223.80Price Target Upside26.83% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)12.81
Revenue Forecast (FY)$17.29B
Bulls Say, Bears Say
Bulls Say
Cash GenerationPersistent, high-quality cash generation gives IQVIA durable financial flexibility: it funds technology investment, share repurchases and strategic deployments without immediate reliance on new equity. Strong OCF and rebounding TTM FCF support reinvestment in data assets and clinical capacity over the next 2–6 months.
Backlog & Bookings VisibilityA multi-year backlog with substantial near-term conversion provides revenue visibility and supports steadier organic growth. Large, recurring R&D bookings reduce short-term demand cyclicality, underpin revenue recognition over coming quarters, and help smooth operational planning and capacity deployment.
Data & AI Competitive AdvantageBroad AI adoption by leading pharma clients reinforces IQVIA's differentiated data-plus-analytics moat. Embedding AI into workflows can raise switching costs, expand addressable services, and drive higher-value, recurring engagements, supporting sustainable commercial momentum and margin mix over the medium term.
Bears Say
Elevated LeverageMaterial leverage constrains capital allocation flexibility and raises interest‑rate sensitivity. With net leverage near 3.6x, management faces tradeoffs among buybacks, M&A, and investment; refinancing activity helps but the debt load can limit downside protection and strategic optionality over the next several quarters.
Margin & Mix PressureMargin compression from adverse FX and a lower pass-through services mix suggests structural volatility in reported profitability. If mix shifts toward lower‑margin full‑service trials or FX tailwinds fade, sustained margin recovery may be delayed, limiting near‑term improvement in operating leverage and cash conversion.
Pass‑Through & Conversion TimingReduced pass‑through bookings and long lags from funding to awards create timing risk for revenue realization and can depress book‑to‑bill metrics. This structural timing mismatch increases short‑to‑medium term uncertainty around revenue cadence and may mute perceived organic momentum despite strong underlying demand.
IQVIA Holdings News
IQV FAQ
What was IQVIA Holdings’s price range in the past 12 months?
IQVIA Holdings lowest stock price was $154.50 and its highest was $247.04 in the past 12 months.
What is IQVIA Holdings’s market cap?
IQVIA Holdings’s market cap is $34.42B.
When is IQVIA Holdings’s upcoming earnings report date?
IQVIA Holdings’s upcoming earnings report date is Jul 28, 2026 which is in 8 days.
How were IQVIA Holdings’s earnings last quarter?
IQVIA Holdings released its earnings results on May 05, 2026. The company reported $2.9 earnings per share for the quarter, beating the consensus estimate of $2.816 by $0.084.
Is IQVIA Holdings overvalued?
According to Wall Street analysts IQVIA Holdings’s price is currently Undervalued.
Does IQVIA Holdings pay dividends?
IQVIA Holdings does not currently pay dividends.
What is IQVIA Holdings’s EPS estimate?
IQVIA Holdings’s EPS estimate is 3.03.
How many shares outstanding does IQVIA Holdings have?
IQVIA Holdings has 166,900,000 shares outstanding.
What happened to IQVIA Holdings’s price movement after its last earnings report?
IQVIA Holdings reported an EPS of $2.9 in its last earnings report, beating expectations of $2.816. Following the earnings report the stock price went up 9.618%.
Which hedge fund is a major shareholder of IQVIA Holdings?
Currently, no hedge funds are holding shares in IQV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IQVIA Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$223.80 (26.83% Upside)
$223.80 (26.83% Upside)
Blogger Sentiment
Neutral
IQV Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 6.5%
Last 30 Days ▲ 6.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
26.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.61%
Trailing 12-Months
Company Description
IQVIA Holdings
IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific. The company's operations are structured into three key divisions: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides a suite of cloud-native applications, complete with implementation services, and offers real-world data solutions designed to empower life sciences and healthcare providers in generating and disseminating evidence crucial for informed decision-making and improving patient outcomes. This division also delivers strategic and operational consulting, including advanced analytics support and outsourcing of commercial processes. Furthermore, it supplies country-level performance metrics detailing pharmaceutical sales, prescribing trends, medical treatments, and promotional activities across diverse channels like retail, hospital, and mail order, with data granularity extending to regional, postal code, and individual prescriber levels. Focusing on clinical trials, the Research & Development Solutions segment offers project management, clinical monitoring, broader clinical trial support, virtual trial capabilities, and strategic planning and design services. It also manages an extensive network of laboratory services, encompassing central, genomic, bioanalytical, ADME, discovery, vaccine, and biomarker analyses. The Contract Sales & Medical Solutions segment is responsible for engaging healthcare professionals and patients, alongside providing scientific strategy and medical affairs support. IQVIA's diverse clientele includes pharmaceutical, biotechnology, medical device and diagnostic, and consumer health companies. The company maintains a strategic collaboration with HealthCore, Inc. Founded in 1982, the firm was formerly known as Quintiles IMS Holdings, Inc. before rebranding as IQVIA Holdings Inc. in November 2017. Its headquarters are located in Durham, North Carolina.
IQV Revenue Breakdown
40.63% Technology & Analytics Solutions
54.54% Research & Development Solutions
4.83% Contract Sales & Medical Solutions
IQV Stock 12 Month Forecast
Average Price Target
$223.80
▲(26.83% Upside)
Technical Analysis
Ownership Overview
0.98% Insiders
27.83% Mutual Funds
0.70% Other Institutional Investors
44.02% Public Companies and
Individual Investors